Zobrazeno 1 - 10
of 183
pro vyhledávání: '"Irene M. Ghobrial"'
Autor:
Justin Cha, Cody J. Boehner, Nikhil C. Munshi, Romanos Sklavenitis-Pistofidis, Kwee Yong, Chip Stewart, Karma Salem, Eliezer M. Van Allen, Jihye Park, Yu-Tzu Tai, Andrew Dunford, Shankara Anand, Lorenzo Trippa, Amaro Taylor-Weiner, Jacob P. Laubach, Mark Bustoros, Benny Zhitomirsky, Robert A. Redd, Selina J Chavda, Irene M. Ghobrial, Shaji Kumar, Paul G. Richardson, Kenneth C. Anderson, François Aguet, Tarek H. Mouhieddine, P. Leif Bergsagel, Gad Getz, Mahshid Rahmat, Tineke Casneuf, Meletios A. Dimopoulos, Liudmila Elagina, Carl Jannes Neuse, Salomon Manier, Elizabeth A. Morgan, Ignaty Leshchiner, Efstathis Kastritis
Publikováno v:
J Clin Oncol
PURPOSE Smoldering multiple myeloma (SMM) is a precursor condition of multiple myeloma (MM) with a 10% annual risk of progression. Various prognostic models exist for risk stratification; however, those are based on solely clinical metrics. The disco
Autor:
Irene M. Ghobrial, Michael Andreeff, Dominique Bonnet, Daniela S. Krause, Simón Méndez-Ferrer, David P. Steensma, John G. Gribben, Robert P. Hasserjian
Publikováno v:
Nature Reviews Cancer
Nat Rev Cancer
Nat Rev Cancer
Haematological malignancies were previously thought to be driven solely by genetic or epigenetic lesions within haematopoietic cells. However, the niches which maintain and regulate daily production of blood and immune cells are now increasingly bein
Autor:
Peter Sabbatini, Stacey Chuma, Rachid Baz, Jacob P. Laubach, Robert A. Redd, Alexandra Savell, Raymond P. Perez, Pamela S. Becker, Patrick Henrick, Kenneth C. Anderson, Oksana Zavidij, Chia Jen Liu, Kalvis Hornburg, Romanos Sklavenitis-Pistofidis, Michael Robbins, Kaitlen Reyes, Paul G. Richardson, Irene M. Ghobrial
Publikováno v:
Clinical Cancer Research. 26:344-353
Purpose: Ulocuplumab (BMS-936564) is a first-in-class fully human IgG4 monoclonal anti-CXCR4 antibody that inhibits the binding of CXCR4 to CXCL12. Patients and Methods: This phase Ib/II study aimed to determine the safety and tolerability of ulocupl
Autor:
Ashraf Badros, Mihaela Obreja, Jesus G. Berdeja, Jonathan L. Kaufman, Ravi Vij, David S. Siegel, Andrzej Jakubowiak, Michael R. Savona, Noopur Raje, Irene M. Ghobrial
Publikováno v:
Clinical Cancer Research. 25:4907-4916
Purpose: The oral proteasome inhibitor oprozomib has shown preclinical antitumor activity. Here, we report phase Ib/II study results investigating single-agent oprozomib in patients with relapsed multiple myeloma and Waldenström macroglobulinemia. P
Autor:
Philippe Armand, Damian R. Handisides, Irene M. Ghobrial, Jacalyn Rosenblatt, Kenneth C. Anderson, Jacquelyn Hedlund, Paul G. Richardson, Henry Dumke, Bradley Rivotto, Stacey Chuma, Robert L. Schlossman, Kenneth H. Shain, Stew Kroll, Patrick Henrick, Chia Jen Liu, Noopur Raje, Michael Gary Martin, Alexandra Savell, Andrew Yee, Craig Reynolds, Kalvis Hornburg, Laura Stampleman, Jacob P. Laubach, Ira Zackon
Publikováno v:
Clinical Cancer Research. 25:478-486
Purpose: The presence of hypoxia in the diseased bone marrow presents a new therapeutic target for multiple myeloma. Evofosfamide (formerly TH-302) is a 2-nitroimidazole prodrug of the DNA alkylator, bromo-isophosphoramide mustard, which is selective
Autor:
Elizabeth O'Donnell, Areej El-Jawahri, Omar Nadeem, Emerentia Agyemang, Irene M. Ghobrial, Yael N Shapiro, Andrew Yee, Cynthia C. Harrington, Jacob P. Laubach, Adam S. Sperling, Paul G. Richardson, Kenneth C. Anderson, Noopur Raje, Clifton C. Mo, Nikhil C. Munshi, Andrew R. Branagan, Jill N. Burke
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S117-S118
Background Multiple myeloma (MM) is an incurable hematologic malignancy requiring long-term, continuous therapy. Despite its chronic and unrelenting course, studies examining quality of life (QOL), psychological distress, and prognostic awareness by
Autor:
Youngil Koh, Lucie Lepine, Miles Prince, Valdas Peceliunas, Sevgi Kalayoglu Besisik, Irene M. Ghobrial, Codina Oprea, Emil Hermansen, Javier de la Rubia, Vania Hungria, Hang Quach, Paula Rodriguez-Otero, Maria-Victoria Mateos, Jin Seok Kim, Christine Devisme, Joaquin Martinez-Lopez, Sandrine Macé, Gurdeep Parmar, Xavier Leleu, Fredrik Schjesvold, Franck Dubin
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S109-S110
Background: High-risk smoldering multiple myeloma (HR-SMM) is associated with a greater risk of progression to symptomatic disease, suggesting the need for early, efficacious therapeutic interventions to improve outcomes. The ongoing, randomized Phas
Autor:
Irene M. Ghobrial, François Aguet, Oksana Zavidij, Sylvia Ann Ujwary, Gad Getz, Romanos Sklavenitis-Pistofidis, Alexandra Savell, Robert A. Redd, Nang Kham Su, Ankit K. Dutta, Nicholas J. Haradhvala, Mark Bustoros
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S38-S39
Background Patients with Smoldering Multiple Myeloma (SMM) are typically observed until progression, but early treatment of high-risk patients may improve outcomes. Clinical and genomic biomarkers can be used to identify SMM patients at high risk of
Autor:
Mark Bustoros, Daisy Huynh, Jorge J. Castillo, Steven P. Treon, Irene M. Ghobrial, Patrick Henrick, Bradley Rivotto, Adriana Perilla-Glen, Mairead Reidy, Chia Jen Liu, Oksana Zavidij, Romanos Sklavenitis-Pistofidis, Lorenzo Trippa, Alexandra Savell, Marzia Capelletti, Kaitlen Reyes
Publikováno v:
Blood. 132:2608-2612
TO THE EDITOR: Waldenstrom macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma associated with immunoglobulin M monoclonal gammopathy.[1][1] The majority of patients carry the L265P mutation in MYD88,[2][2] whereas 40% of patients carry mutat
Autor:
Steven P. Treon, Christopher J. Patterson, Guang Yang, Jacob P. Laubach, Zachary R. Hunter, Andrew R. Branagan, Xia Liu, Irene M. Ghobrial, Kirsten Meid, Jorge J. Castillo, Lian Xu, Ranjana H. Advani, M. Lia Palomba, Joshua Gustine
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(6)
PURPOSE We report the long-term findings and final analysis of a pivotal multicenter trial of ibrutinib monotherapy in previously treated patients with Waldenström macroglobulinemia (WM). PATIENTS AND METHODS Sixty-three symptomatic patients with me